Myeloproliferative Neoplasms News

SAN DIEGO — Treatment with a selective PIM1 kinase inhibitor showed positive clinical reactions in a sample of 23 patients with relapsed/refractory myelofibrosis, according to preliminary data presented at ASH Annual Meeting.

SAN DIEGO — Treatment with fedratinib led to “superior” spleen volume reduction and symptom response rates in patients with myelofibrosis previously treated with ruxolitinib, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Researchers found JAK-STAT mutations in a predominance of a cohort of adults with fusion-free hypereosinophilia with features suggesting myeloid neoplasms, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Pacritinib may provide a “unique survival advantage” for patients with myelofibrosis also exhibiting moderate or severe thrombocythemia, according to data from the PERSIST-2 study, presented at ASH Annual Meeting and Exposition.

In a special scientific session on race and science at ASH Annual Meeting an Exposition, Saad Z. Usmani, MD, MBA, FACP, FRCP, examined clinical trial inclusion from an investigator’s perspective.

SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.

SAN DIEGO — An international group of researchers developed an artificial intelligence-based algorithm that differentiates prefibrotic primary myelofibrosis from essential thrombocythemia during pathological analysis, study findings showed.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.

Three physicians have been elected to serve in leadership roles on ASH’s executive committee.

The combination of pelabresib plus ruxolitinib significantly increased the proportion of patients with myelofibrosis who achieved a clinically meaningful reduction in spleen volume, according to the agent’s manufacturer.